Home / Business and Economy / US FDA Inspects Emcure's Sanand Facility, Issues 7 Observations
US FDA Inspects Emcure's Sanand Facility, Issues 7 Observations
16 May
Summary
- US FDA inspected Emcure Pharma's Gujarat facility from May 6-15, 2026.
- The inspection resulted in seven procedural observations from the US FDA.
- Emcure Pharmaceuticals is addressing these observations and will respond promptly.
The United States Food and Drug Administration (US FDA) conducted a current Good Manufacturing Practices (cGMP) inspection at Emcure Pharmaceuticals Ltd's formulations facility in Sanand, Ahmedabad, Gujarat. This inspection took place from May 6 to May 15, 2026. Following the inspection, the company received a Form 483, which noted seven observations. Emcure Pharmaceuticals characterized these observations as procedural and confirmed they are being addressed. The company stated its commitment to responding to the US FDA comprehensively within the required period. The facility in question is situated in G.I.D.C., Taluka-Sanand, Ahmedabad, Gujarat. Separately, Emcure Pharma reported strong financial results for the fourth quarter, with net profit rising 29% year-on-year to ₹243 crore. Revenue increased by 16.7% to ₹2,469.7 crore, driven by a significant 25.7% rise in international business sales.
